Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Genetic mutations in amyloid precursor protein (APP) have been found to contribute to the early-onset or prevention of Alzheimer’s disease. The A673V variant of APP is associated with early-onset familial Alzheimer’s disease. The contribution of APP A673V to Alzheimer’s pathology is suggested to involve an elevated affinity to β-secretase, increased amyloid-beta (Aβ) production, Aβ aggregation, and neural toxicity.
iCell GABANeurons APP A673V were developed as a cellular model to investigate the genetic predisposition to early-onset Alzheimer’s Disease using a clinically relevant familial APP variant. The heterozygous mutation was engineered into apparently healthy normal induced pluripotent stem cells, followed by differentiation into cortical neurons that exhibit a majority GABAergic phenotype.
Additionally, iCell GABANeurons APP A673T cells with the protective APP variant are ideal for studying genetic protection against Alzheimer’s disease.
Features of iCell GABANeurons A673V:
View all Alzheimer’s disease cell models here.
iCell GABANeurons APP A673V are engineered for an Alzheimer’s disease-associated gene mutation that provides a uniquely relevant biological Alzheimer’s disease model.
Terminally differentiated from human iPS cells, iCell GABANeurons APP A673V are ≥95% pure neuronal population with a majority of GABAergic neurons.
Commercial quantities of consistent GABA phenotype batches ensure reproducible large-scale drug screening programs.
iCell GABANeurons APP A673V are shipped cryopreserved with optimized media. Simply thaw and use.